Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature

Gynecol Oncol Rep. 2024 Aug 22:55:101486. doi: 10.1016/j.gore.2024.101486. eCollection 2024 Oct.

Abstract

•Mirvetuximab soravtansine-gynx should be recognized as a cause of drug-induced interstitial lung disease (ILD).•Radiographic manifestations of mirvetuximab soravtansine-gyn induced ILD include organizing pneumonia pattern.•Interstitial lung disease related to mirvetuximab soravtansine-gyn can cause high morbidity.•Corticosteroids are commonly used in drug-induced interstitial lung disease and should be considered when encountering ILD related to mirvetuximab.•Changes to manufacturer dosing guidelines for grade 1 pneumonitis related to mirvetuximab soravtansine-gyn need to be considered.

Publication types

  • Case Reports